# Raj Pruthi

Type: Person

Source: Biotech Intelligence Brief — https://getbiobrief.com/entity/raj-pruthi
Canonical HTML page: https://getbiobrief.com/entity/raj-pruthi

## Timeline

- **2027**: Data Readout — Expected top-line data from Phase 3 adjunctive MDD trials.
- **2026-03-19**: Earnings Call — CEO Sergio Traversa provides update on Reliance II and Reliance III trials.
- **2026**: Enrollment Completion — Anticipated completion of enrollment for the pivotal Reliance II study.
- **2025-12-31**: Q4 2025 Close — Relmada concludes fiscal year with focus on Phase 3 enrollment.

## Recent coverage (1 stories)

### Relmada Therapeutics Advances REL-1017 Trials Amid Q4 2025 Financial Review
2026-03-20 14:55:34 · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Relmada Therapeutics reported its Q4 2025 results, highlighting progress in its Phase 3 REL-1017 program for major depressive disorder. The company remains focused on completing enrollment for its pivotal trials while maintaining a strategic cash position to reach key clinical milestones.
Full story: https://getbiobrief.com/story/relmada-therapeutics-q4-2025-earnings-analysis

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getbiobrief.com/guides/methodology for the full editorial methodology.